We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PCOR:NYSEProcore Technologies, Inc. Analysis

Data as of 2026-04-23 - not real-time

$53.40

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Procore Technologies (PCOR) is trading at $53.4, which sits below its 20‑day (54.42) and 50‑day (54.96) simple moving averages, signaling a short‑term bearish bias. The stock’s price is hovering above the computed support level of $46.64 but well under the resistance of $59.05, leaving limited upside in the near term. Technical momentum is mixed: the RSI at 46.3 is neutral, while the MACD histogram is positive, giving a bullish signal despite the overall bearish trend.
Fundamentally, the company posted a 15.6% revenue growth year‑over‑year and maintains a strong 79.6% gross margin, yet operating and profit margins remain negative (-11.5% and -7.6% respectively). Cash flow is solid with $300 M operating cash flow and $239 M free cash flow, but the balance sheet shows a high debt‑to‑equity ratio of 6.28, raising leverage concerns. Analysts average a “buy” rating with target prices around $71‑$73, implying roughly a 30% upside, while the DCF‑derived fair value of $44.3 suggests the market is pricing in a premium for expected turnaround.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMAs indicating bearish bias
  • Support level at $46.64 offers downside cushion
  • Increasing volume and bullish MACD histogram suggest potential short‑term bounce

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 15.6% and strong gross margin
  • Forward EPS of $2.25 and analyst target median of $73
  • Robust operating and free cash flow despite current losses

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic positioning in the growing construction‑software market
  • Improving profitability outlook as margins normalize
  • High beta (1.38) and volatility (55% 30‑day) imply higher reward for patient investors

Key Metrics & Analysis

Financial Health

Revenue Growth15.60%
Profit Margin-7.62%
P/E Ratio23.7
ROE-7.90%
ROA-3.39%
Debt/Equity6.28
P/B Ratio6.4
Op. Cash Flow$300.3M
Free Cash Flow$239.6M
Industry P/E37.0

Technical Analysis

TrendBearish
RSI46.3
Support$46.64
Resistance$59.05
MA 20$54.42
MA 50$54.96
MA 200$66.59
MACDBullish
VolumeIncreasing
Fear & Greed Index86.95

Valuation

Fair Value$44.32
Target Price$71.00
Upside/Downside32.96%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.38
Volatility55.12%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.